

**TRADEMARK ASSIGNMENT**

Electronic Version v1.1  
 Stylesheet Version v1.1

|                       |                          |
|-----------------------|--------------------------|
| SUBMISSION TYPE:      | NEW ASSIGNMENT           |
| NATURE OF CONVEYANCE: | RELEASE BY SECURED PARTY |

**CONVEYING PARTY DATA**

| Name   | Formerly | Execution Date | Entity Type       |
|--|----------|----------------|-------------------|
| Credit Suisse AG as success of<br>Credit Suisse First Boston |          | 01/31/2011     | bank: SWITZERLAND |

**RECEIVING PARTY DATA**

|                 |                            |
|-----------------|----------------------------|
| Name:           | King Pharmaceuticals, Inc. |
| Street Address: | 501 Fifth Street           |
| City:           | Bristol                    |
| State/Country:  | TENNESSEE                  |
| Postal Code:    | 37620                      |
| Entity Type:    | CORPORATION: TENNESSEE     |

|                 |   |
|-----------------|---|
| Name:           | King Pharmaceuticals Research and Development, Inc. |
| Street Address: | 4000 Centre Green Way                               |
| City:           | Cary  |
| State/Country:  | NORTH CAROLINA                                      |
| Postal Code:    | 27513   |
| Entity Type:    | CORPORATION: DELAWARE                               |

**PROPERTY NUMBERS Total: 10**

| Property Type        | Number  | Word Mark               |
|----------------------|---------|-------------------------|
| Registration Number: | 1812659 | ALTACE                  |
| Registration Number: | 2031644 | MONARCH PHARMACEUTICALS |
| Registration Number: | 1040408 | CORGARD                 |
| Registration Number: | 1170890 | CORZIDE                 |
| Registration Number: | 0926416 | SILVADENE               |
| Registration Number: | 0684353 | TIGAN                   |
| Registration Number: | 2927077 | KING                    |
| Registration Number: | 2927079 | KING PHARMACEUTICALS    |

**TRADEMARK**

**900182911**

**REEL: 004465 FRAME: 0679**

**CH \$265.00 1812659**

|                      |         |                      |
|----------------------|---------|----------------------|
| Registration Number: | 2927078 | KING PHARMACEUTICALS |
| Registration Number: | 2656254 | KINGKARE             |

**CORRESPONDENCE DATA**

Fax Number: (202)778-5299  
*Correspondence will be sent via US Mail when the fax attempt is unsuccessful.*  
Phone: 202.662.5299  
Email: trademarks@cov.com  
Correspondent Name: Kathleen T. Gallagher-Duff  
Address Line 1: 1201 Pennsylvania Avenue, N.W.  
Address Line 4: Washington, DISTRICT OF COLUMBIA 20004

|                         |                    |
|-------------------------|--------------------|
| ATTORNEY DOCKET NUMBER: | 029459.00030       |
| NAME OF SUBMITTER:      | Cheryl L. Fountain |
| Signature:              | /cheryllfountain/  |
| Date:                   | 02/02/2011         |

**Total Attachments: 3**  
source=King 2002 Security Agreement TM Release#page1.tif  
source=King 2002 Security Agreement TM Release#page2.tif  
source=King 2002 Security Agreement TM Release#page3.tif

## Release of Security Interest in Trademarks

January 31, 2011

**WHEREAS**, KING PHARMACEUTICALS, INC., a Tennessee corporation, as Borrower (the “**King**”), certain of its subsidiaries, as Guarantors, and CREDIT SUISSE AG, as successor to Credit Suisse First Boston, Cayman Islands branch (“**Credit Suisse**”), in its capacity as Collateral Agent for the Secured Parties (as each term is defined in the Security Agreement (as defined below)), entered into that certain Security Agreement (the “**Security Agreement**”) dated as of April 23, 2002;

**WHEREAS**, the Security Agreement was recorded with the United States Patent and Trademark Office on September 4, 2002 on Reel No. 002575 Frame No. 0157;

**WHEREAS**, under the Security Agreement, King and King Pharmaceuticals Research and Development, Inc. (together, the “**Assignee**”) granted to Credit Suisse a security interest in certain Collateral (as defined in the Security Agreement), including those items set forth on Schedule 1 (collectively, the “**Released Trademark Collateral**”);

**WHEREAS**, the parties agree and acknowledge that the foregoing United States Patent and Trademark Office assignment record may list Credit Suisse AG in a capacity other than Collateral Agent, and that the security interest was granted to, and this release is correctly made by, Credit Suisse, as Collateral Agent; and

**WHEREAS**, Credit Suisse desires to release the security interest granted by the Assignee under the Security Agreement in the Released Trademark Collateral.

**NOW, THEREFORE**, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Credit Suisse, as Collateral Agent for the Secured Parties, does hereby unconditionally, irrevocably and absolutely terminate, release, extinguish and forever discharge the security interest granted under the Security Agreement in the Released Trademark Collateral, together with all of the goodwill of the business connected with the use of, or symbolized by, such Released Trademark Collateral, and hereby unconditionally, irrevocably and absolutely assigns, transfers and conveys to the Assignee all right, title and interest of Credit Suisse in, to and under such Released Trademark Collateral and such goodwill granted under the Security Agreement. This Release of Security Interest in Trademarks shall be binding upon Credit Suisse’s legal representatives, assigns and successors, and upon the Secured Parties and their legal representatives, assigns and successors. Credit Suisse also hereby authorizes, and requests, the Director of the United States Patent and Trademark Office or his delegate to record this Release of Security Interest in Trademarks against the Released Trademark Collateral.

*[signature page to follow]*

IN WITNESS WHEREOF, Credit Suisse has caused this Release of Security Interest in Trademarks to be duly executed by its officers thereunto duly authorized as of the day and year first above written.

CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH

By:

Name:

Title:

By:

Name:

Title:

VIPUL DHADDA  
ASSOCIATE

*[signature page – King Pharmaceuticals, Inc. trademark release]*

**Schedule 1**

**KING PHARMACEUTICALS, INC.**

**U.S. TRADEMARK REGISTRATIONS**

| <b>Trademark</b>                            | <b>Registration No.</b> | <b>Registration Date</b> |
|---|-------------------------|--------------------------|
| ALTACE                                      | 1,812,659               | 21-Dec-1993              |
| MONARCH<br>PHARMACEUTICALS and Design       | 2,031,644               | 21-Jan-1997              |
| CORGARD                                     | 1,040,408               | 01-Jun-1976              |
| CORZIDE                                     | 1,170,890               | 29-Sep-1981              |
| SILVADENE                                   | 926,416                 | 04-Jan-1972              |
| TIGAN                                       | 684,353                 | 01-Sep-1959              |
| KING and Crown Design                       | 2,927,077               | 22-Feb-2005              |
| KING PHARMACEUTICALS                        | 2,927,079               | 22-Feb-2005              |
| KING PHARMACEUTICALS<br>within Crown Design | 2,927,078               | 22-Feb-2005              |
| KINGKARE                                    | 2,656,254               | 03-Dec-2002              |